Bringing hope to the over 115 million people worldwide with MASH

Currently, the only treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis is a liver transplant. We hope to change that.

Learn More

Our galectin-3 inhibitor GR-MD-02 (belapectin) may hold the key to many diseases

The galectin-3 protein is directly involved in many inflammatory, fibrotic, and malignant diseases.

Learn more

Saving lives in cancer immunotherapy

Inhibiting galectin-3 may allow the body’s own immune system to target and destroy cancer cells.

Learn More

Combating fatty liver disease and MASH cirrhosis

MASH cirrhosis is rapidly becoming the number one reason for liver transplants.

Learn More

The NAVIGATE study clinically focused on MASH cirrhosis

Do you qualify for the NAVIGATE Study?

Learn More

Galectin Therapeutics is working to improve the lives of patients with MASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in MASH cirrhosis.